Clinical Ophthalmology (Oct 2020)
Human Platelets and Derived Products in Treating Ocular Surface Diseases – A Systematic Review
Abstract
Jingjing You,1,2 Chris Hodge,1,3– 5 Monira Hoque,4 Constantinos Petsoglou,1,4 Gerard Sutton1,3,4 1Save Sight Institute, Sydney Medical School, University of Sydney, Sydney, NSW, Australia; 2School of Optometry and Vision Science, UNSW Sydney, Sydney, NSW, Australia; 3Vision Eye Institute, Chatswood, Sydney, NSW, Australia; 4NSW Tissue Bank, Sydney, NSW, Australia; 5Graduate School of Health, University of Technology Sydney, Sydney, NSW, AustraliaCorrespondence: Jingjing YouSave Sight Institute, Sydney Medical School, University of Sydney, 8 Macquarie Street, Sydney 2001, AustraliaEmail [email protected]: Human platelet products have emerged as an alternative treatment for a range of ocular surface diseases such as dry eye and corneal ulceration. With significant therapeutic potential and increasing popularity, this study aimed to conduct a systematic review to detail the various production methods involved in generating platelet-derived products, compare and analyze clinical findings across available studies, and disseminate the relative advantages, limitations, and challenges of using platelet products to treat ocular surface disease. Thirty-eight clinical studies were identified, excluding studies conducted in animals and non-English language. Studies reported clinical outcomes, which included ocular surface disease index, best-corrected visual acuity, and corneal fluorescein staining. Most clinical studies reported improved patient signs and symptoms with an increasing variety of human platelet products including platelet rich plasma eye drops, human platelet lysate and platelet gels. However, due to variations in production methods, and study designs as well as confusing terminology, it was suggested that characterization of platelet products is needed for proper evaluation across studies.Keywords: platelet rich plasma, human platelet lysate, dry eye syndrome
